Skye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 119,379 Shares of Stock

Posted by Tyrone Williams on Sep 25th, 2026

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report) major shareholder 5Am Partners Vii, Llc sold 119,379 shares of the stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $1.61, for a total value of $192,200.19. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

5Am Partners Vii, Llc also recently made the following trade(s):

On Tuesday, September 22nd, 5Am Partners Vii, Llc sold 28,700 shares of Skye Bioscience stock. The stock was sold at an average price of $1.65, for a total value of $47,355.00.
On Wednesday, September 16th, 5Am Partners Vii, Llc sold 33,892 shares of Skye Bioscience stock. The stock was sold at an average price of $1.91, for a total value of $64,733.72.
On Thursday, August 20th, 5Am Partners Vii, Llc sold 962 shares of Skye Bioscience stock. The stock was sold at an average price of $2.56, for a total value of $2,462.72.
On Wednesday, August 19th, 5Am Partners Vii, Llc sold 8,517 shares of Skye Bioscience stock. The shares were sold at an average price of $2.80, for a total value of $23,847.60.
On Tuesday, August 18th, 5Am Partners Vii, Llc sold 37,500 shares of Skye Bioscience stock. The shares were sold at an average price of $3.04, for a total transaction of $114,000.00.

Skye Bioscience Trading Down 5.6%

Shares of Skye Bioscience stock opened at $1.70 on Friday. The firm has a fifty day simple moving average of $3.13 and a 200-day simple moving average of $4.97. The stock has a market capitalization of $7.53 million, a price-to-earnings ratio of -0.17 and a beta of 2.90. Skye Bioscience, Inc. has a 1-year low of $1.50 and a 1-year high of $39.92.

Skye Bioscience (NASDAQ:SKYE – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. As a group, research analysts predict that Skye Bioscience, Inc. will post -5.04 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Skye Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $64.00.

Check Out Our Latest Report on Skye Bioscience

About Skye Bioscience

(Get Free Report)

Skye Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that modulate the endocannabinoid system, a network involved in metabolism, inflammation and other physiological processes. The company’s research is centered on therapies designed to influence cannabinoid receptors outside the central nervous system, with the goal of addressing disease while avoiding certain side effects associated with earlier centrally acting cannabinoid drugs.

Skye’s lead investigational product is nimacimab, a monoclonal antibody that targets the cannabinoid receptor 1 (CB1).